Receptor Partners

Receptor is a venture capital firm established in 2017 and located in New York, New York. The firm focuses on investing in companies within the psychedelic medicine sector, aiming to support the development and commercialization of innovative therapeutic solutions. By concentrating on this emerging field, Receptor seeks to capitalize on the growing interest and research surrounding psychedelics for mental health treatment and other medical applications.

Zack Sherman

Co-Founder

2 past transactions

Mycrodose

Seed Round in 2021
Mycrodose Therapeutics is a US-Based pharmaceutical company specialized in the development of advanced drug delivery (ADD) systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. The company is in the parallel development of two of its four core technologies; a psilocybin transdermal delivery system, Ketamine oral mucosa delivery system.

Mindstate Design Labs

Pre Seed Round in 2021
Mindstate Design Labs is a preclinical-stage biotechnology company focused on creating psychedelic-inspired therapeutics to address challenging mental health conditions. The company employs a unique platform that combines natural history and computational methods to forecast the acute effects of serotonergic agonists on humans. This innovative approach allows healthcare institutions to explore altered states of consciousness as potential treatments for various mental and behavioral health disorders. By developing these advanced therapeutics, Mindstate Design Labs aims to offer new solutions for individuals suffering from intractable mental health issues.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.